Azenta, Inc. is a leading provider of life sciences solutions, focusing on enabling advancements in research and development through its innovative technologies and services. The company specializes in genomic solutions, including sample storage, processing, and logistics, aimed at supporting biobanking and accelerating the discovery of new therapies. With a commitment to enhancing global health, Azenta's offerings cater to the needs of pharmaceutical and biotechnology companies, academic institutions, and research organizations, ultimately striving to improve the efficiency and effectiveness of life sciences research. Read More
Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $148.6 million. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 24.6% in the afternoon session after it reported mixed fourth-quarter results that failed to impress investors.
Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $148.6 million. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 7.3% in the afternoon session after Evercore ISI Group upgraded the company's rating to "Outperform" from "In-Line" and raised its price target.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Azenta trades at $34.56 and has moved in lockstep with the market. Its shares have returned 12.3% over the last six months while the S&P 500 has gained 11.7%.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
In a dynamic period for the financial markets, several public companies are making headlines with significant corporate actions. Azenta Inc. (NASDAQ: AZTA) and Fabasoft AG (XTRA: FSY) have recently unveiled substantial share buyback programs, signaling strong confidence in their future prospects and a commitment to enhancing shareholder value. These strategic
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 15.5%, nearly mirrorring the S&P 500.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 4.2% in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.
Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 14.9% in the afternoon session after it reported third-quarter 2025 results that featured better-than-expected revenue and profitability.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per share was in line with analysts’ consensus estimates.
Azenta (AZTA) reports Q4 FY2025 results, beating EPS estimates with $0.21 and slightly missing on revenue. The stock rose on the positive earnings news.
